Work

Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx377.027

Authors: K. Lewis, J. Larkin, A. Ribas, K.T. Flaherty, G.A. McArthur, P.A. Ascierto, B. Dréno, E. McKenna, Q. Zhu, Y. Mun, A. Hauschild

Institutions: University of Colorado Cancer Center, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Massachusetts General Hospital, Peter MacCallum Cancer Centre, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Nantes Université, Genentech, University Hospital Schleswig-Holstein

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2761851877

FWCI:

Cites:

Cited by:

Related to: 10